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Mechanisms of antioxidant and pro-oxidant effects of a-lipoic
acid in the diabetic and nondiabetic kidney.
Background. a-Lipoic acid is a potent antioxidant that im-
proves renal function in diabetes by lowering glycemia, how-
ever, the mechanisms by which a-lipoic acid exerts its antioxi-
dant effects are not completely understood.
Methods. Metabolic parameters, renal function, and
morphology, nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activity and subunit expression were ana-
lyzed in nondiabetic and streptozotocin-induced diabetic rats
fed normal rat chow (control) with or without a-lipoic acid
(30 mg/kg body weight) for 12 weeks.
Results. Blood glucose was increased with diabetes (nondi-
abetic + control 89 ± 3 mg/dL and diabetic + control 336 ±
28 mg/dL) and was similar with a-lipoic acid treatment (di-
abetic + a-lipoic acid 351 ± 14 mg/dL). In contrast, a-lipoic
acid attenuated albuminuria (nondiabetic + control 8.9 ± 1.3
mg/day; diabetic + control 28.1 ± 4.6 mg/day; and diabetic +
a-lipoic acid 17.8 ± 1.2 mg/day) associated with diabetes. Sim-
ilarly, a-lipoic acid attenuated glomerulosclerosis (nondiabetic
+ control 0.22 ± 0.01; diabetic + control 0.55 ± 0.04; diabetic
+ a-lipoic acid 0.36 ± 0.03), tubulointerstitial fibrosis (nondi-
abetic + control 0.42 ± 0.18; diabetic + control 1.52 ± 0.05;
diabetic + a-lipoic acid 1.10 ± 0.05), superoxide anion (O·−2 )
generation (nondiabetic +control 15.8 ± 1.7; diabetic +control
87.1 ± 3.5; diabetic + a-lipoic acid 25.5 ± 3.3 RLU/mg pro-
tein), and urine 8-isoprostane (8-iso) excretion (nondiabetic +
control 7.4 ± 1.4; diabetic + control 26.0 ± 4.5; diabetic + a-
lipoic acid 19.6 ± 5.6 ng/day) associated with diabetes. a-Lipoic
acid also reduced kidney expression of NADPH oxidase sub-
units p22phox and p47phox. Surprisingly, a-lipoic acid appears
to cause pro-oxidant effects in nondiabetic animals, resulting
in increased albuminuria (nondiabetic + a-lipoic acid 14.2 ±
1.2 mg/day), increase in plasma creatinine levels (nondiabetic
+ control 59 ± 6; diabetic + control 68 ± 6; nondiabetic +
a-lipoic acid 86 ± 9; diabetic + a-lipoic acid 69 ± 7 lmol/L),
exacerbated glomerulosclerosis and tubulointerstitial fibrosis,
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increased O·−2 generation, up-regulated p22phox and p47phox
expression and increased 8-iso excretion.
Conclusion. We conclude that a-lipoic acid improves albu-
minuria and pathology in diabetes by reducing oxidative stress,
while in healthy animals, a-lipoic acid may act as a pro-oxidant,
contributing to renal dysfunction.
Hyperglycemia-induced oxidative stress has been im-
plicated in the pathophysiology of diabetic nephropathy
[1, 2]. Recent findings have suggested that increased in-
tracellular glucose levels, as a result of increased glucose
uptake into the kidney, lead to the formation of advanced
glycation end products (AGEs). AGEs in turn stimulate
local production of oxygen free radicals leading to oxida-
tive stress [1–4]. In uncontrolled diabetes, the levels of
superoxide dismutase, the enzyme responsible for inac-
tivating one such oxygen radical [i.e., superoxide anion
(O·−2 )], are decreased in the kidney [5, 6]. Furthermore,
other factors known to be up-regulated in diabetes, in-
cluding angiotensin II (Ang II), have also been shown
to increase formation of oxygen radicals, leading to
oxidative tissue damage [7, 8]. Ang II up-regulates
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase, whose product, O·−2 , can interact with nitric oxide
to form peroxynitrite [7, 9–12]. Nitric oxide, a potent va-
sodilator and an antiproliferative agent, has been shown
to be beneficial in preventing oxidative end-organ dam-
age [7, 9–12]. These studies clearly indicate that prevent-
ing oxidative stress is beneficial in preventing abnormal
regulation of cellular processes that contribute to the de-
velopment and pathogenesis of diabetic renal disease.
Thus far, treatments with antioxidants, including vita-
mins E and C and taurine, have had limited success in pre-
venting the progression of diabetic renal complications
[13–15]. Both human and animal studies have shown that
high doses of vitamin E fail to prevent albuminuria while
lower doses exacerbate renal injury [16, 17]. These stud-
ies stress the importance of developing novel antioxidant
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treatments for reducing the incidence and attenuating the
progression of diabetic complications.
a-Lipoic acid is a sulfur-containing coenzyme involved
in mitochondrial dehydrogenase reactions leading to
adenosine triphosphate (ATP) formation [18, 19]. a-
Lipoic acid, along with its major metabolite dihydrolipoic
acid (DHLA), is a potent antioxidant via scavenging of
oxygen free radicals, redox interaction with other antiox-
idants [20, 21], and inhibition of lipid peroxidation [6].
The beneficial effects of a-lipoic acid in diabetes have
long been recognized, however, these beneficial effects
have mainly been attributed to its glycemic control [22].
More recently, the effects of a-lipoic acid in the treat-
ment of diabetic end-organ complications, including dia-
betic nephropathy, have been reported [6, 21, 23, 24]. In
diabetic neuropathy, a-lipoic acid improves blood flow
and reduces oxidative stress in the distal nerves [25]. In
early diabetes, a-lipoic acid decreases vascular endothe-
lial growth factor (VEGF) expression and hypoxia in the
retina [26]. In diabetic nephropathy, a-lipoic acid has
been shown to prevent renal insufficiency, glomerular
mesangial matrix expansion, and glomerulosclerosis by
restoring glutathione and reducing malondialdehyde lev-
els [22]. The aim of our study was to further elucidate the
mechanisms by which a-lipoic acid exerts its antioxidant
effects and provides renoprotection in diabetic nephropa-
thy.
METHODS
Animal model
Male Sprague-Dawley rats (Harlan, ∼200 g) were ran-
domly divided into four treatment groups: nondiabetic on
control (normal rat chow) diet, nondiabetic on a-lipoic
acid (normal rat chow containing a-lipoic acid) diet, di-
abetic on control diet, and diabetic on a-lipoic acid diet,
with N = 4 to 6 animals per group. a-Lipoic acid diet
was custom prepared by Harlan Teklad and contained
400 mg/kg of a-lipoic acid. The rats were supplemented
with a-lipoic acid at a dose of 30 mg a-lipoic acid/kg body
weight per day. The diabetic rats were given additional
chow without a-lipoic acid to make up the difference in
the food intake. Following an overnight fast, the animals
were either given a single intraperitoneal injection of 0.1
mol/L citrate buffer, pH 4.5 (nondiabetic) or 55 mg/kg
streptozotocin in 0.1 mol/L citrate buffer (diabetic). The
diabetic animals were given daily injections of insulin
(4 to 6 U) (Lantus) (Aventis Pharmaceuticals Inc., Kansas
City, MO, USA) to maintain blood glucose levels be-
tween 250 and 400 mg/dL. During the treatment period
(12 weeks), the animals were placed in metabolic cages
every 4 weeks and urine samples collected for the mea-
surement of albumin excretion and creatinine clearance.
After 12 weeks of treatment, the animals were anes-
thetized with sodium pentobarbital (40 mg/kg intraperi-
toneally) and their femoral vessels catheterized. Sys-
temic blood pressure was monitored electronically using
Cardiomax-II (Columbus Instruments, Columbus, OH,
USA) blood pressure analyzer. Following blood pres-
sure measurements, blood samples were collected by
cardiac puncture for measurement of plasma creatinine.
An abdominal incision was made, the right kidney was
removed, dissected into cortex and medulla, and snap-
frozen in liquid nitrogen for O·−2 measurement and
Western blot analysis. The left kidney was perfused
first with ice-cold phosphate-buffered saline (PBS) un-
til cleared of blood and then with 4% paraformaldehyde
for morphologic analysis and immunohistochemistry.
Plasma creatinine
Plasma creatinine concentrations were determined us-
ing a Beckman Creatinine Analyzer II (Brea, CA, USA)
with the modified Jaffe´ rate method, according to the
manufacturer’s instructions.
Urine albumin excretion (UAE)
Urine albumin concentration was determined using a
Nephrat II Albumin Kit (Exocell, Inc., Philadelphia, PA,
USA) according to the manufacturers’ protocol.
Morphology
Four percent paraformaldehyde-fixed tissue was em-
bedded in paraffin and sectioned at 4 lm for morpho-
logic analysis. The sections were stained with periodic
acid-Schiff (PAS) (for demonstration of glycogen con-
tent) and Masson’s trichrome (for demonstration of col-
lagen deposition).
Glomerulosclerotic index
PAS-stained sections were examined using a Nikon
Eclipse E600 light microscope. Ten sections and 80
glomeruli per section were randomly selected and the
degree of glomerulosclerosis determined using a semi-
quantitative scoring method as previously described [27].
Index of tubulointerstitial fibrosis
Masson’s trichome-stained sections were examined us-
ing a Nikon Eclipse E600 light microscope. Forty sections
were randomly selected, and the degree of tubulointersti-
tial fibrosis determined using a semiquantitative scoring
method as previously described [28].
NADPH-stimulate O·−2 generation
O·−2 generation in response to stimulation with
NADPH was assessed by lucigenin-enhanced chemilu-
minescence as previously described [29]. Briefly, cortical
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and medullary tissues were homogenized in PBS
then incubated with 5 lmol/L lucigenin and the ox-
idase reaction stimulated by addition of 1 mmol/L
NADPH. The background-adjusted chemiluminescence
signal was sampled every second for 10 minutes and
recorded using a tube luminometer with automated in-
jector (AutoLumatPlus LB 953) (EG&G Berthhold,
Germany).
Renal excretion of 8-iso prostaglandin F2a (PGF2a)
8-iso PGF2a was assessed as previously described [30].
Briefly, total 8-iso PGF2a was purified from urine sam-
ples using a phenylboronic acid column (Varian Inc., Palo
Alto, CA, USA) and eluted with ethyl acetate containing
1% methanol and assayed with an enzyme immunoassay
procedure (Cayman Chemical, Ann Arbor, MI, USA).
Imunohistochemistry
Paraffin sections were incubated with 10% nonimmune
goat serum, followed by incubation with monoclonal
antibodies directed against p22phox [31] and p47phox
[32] for 3 hours at room temperature. The positive im-
munoreaction was detected using the Envision Plus Per-
oxidase Kit (Dako Corporation, Carpentaria, CA, USA)
and by counterstaining with Mayer’s hematoxylin. Sec-
tions incubated with 10% nonimmune goat serum in-
stead of the primary antiserum were used as negative
controls.
Western blotting
Homogenized samples from the renal cortex and
medulla were separated on 18% sodium dodecyl sul-
fate (SDS-PAGE) gels and the proteins were trans-
ferred to nitrocellulose membranes. The membranes
were blocked with 5% nonfat milk, followed by primary
antibodies as described for immunohistochemistry at 4◦C
overnight. The membranes were washed and incubated
with horseradish peroxidase-conjugated goat antimouse
IgG, and the proteins were visualized by chemilumines-
cence (KPL, Gaithersburg, MD, USA). The densities of
specific bands were quantitated by densitometry using
Scion Image beta (version 4.02) software. Band densities
were normalized to the total amount of protein loaded
in each well, as determined by densitometric analysis of
gels stained with Coomassie blue.
Statistical analysis
Data are expressed as mean ± SEM, except for albu-
minuria, which is expressed as geometric mean x/÷ toler-
ance factor, and were analyzed with a two-way analysis
of variance (ANOVA) followed by a Bonferroni post hoc
test, using the SigmaStat software (Jandel Scientific, San
Table 1. Effects of a-lipoic acid on body and kidney weight and
blood glucose
Control a-Lipoic acid
Nondiabetic Diabetic Nondiabetic Diabetic
Body weight g 440 ± 12 347 ± 23b 472 ± 13a 386 ± 26b
Kidney weight g 1.2 ± 0.1 1.7 ± 0.1b 1.3 ± 0.1 1.4 ± 0.1a
Kidney/body 2.8 ± 0.1 4.9 ± 0.7c 2.6 ± 0.05 3.1 ± 0.2a
weight
Blood glucose 89 ± 3 336 ± 28c 92 ± 3 352 ± 14c
mg/dL
Mean arterial 119 ± 9 122 ± 14 117 ± 13 120 ± 11
pressure mm Hg
Data are expressed as mean ± SEM.
aP < 0.05; bP < 0.05 vs. nondiabetic in same treatment group; cP < 0.01 vs.
control in same metabolic state.
Rafael, CA, USA). Differences were considered statisti-
cally significant at P < 0.05.
RESULTS
Metabolic parameters and blood pressure
Compared to nondiabetic + control animals, body
weight in the diabetic + control group was decreased
by 1.2-fold. Similarly, body weight in the diabetic + a-
lipoic acid group decreased by 1.2-fold compared to non-
diabetic + a-lipoic acid (Table 1). Kidney weight was
increased by 1.4-fold in the diabetic + control group com-
pared to nondiabetic + control but was not significantly
changed in the diabetic + a-lipoic acid group, as com-
pared to nondiabetic + a-lipoic acid (Table 1). Kidney to
body weight ratio was also increased in the diabetic+ con-
trol group compared to nondiabetic + control (1.8-fold),
whereas kidney/body weight remained similar in nondi-
abetic + a-lipoic acid and diabetic + a-lipoic acid ani-
mals (Table 1). Overall, a-lipoic acid treatment resulted
in significant reductions in kidney weight (1.2-fold) and
kidney/body weight ratio (1.6-fold) in diabetic animals
(Table 1).
Blood glucose was threefold higher in diabetic com-
pared to the nondiabetic group (Table 1). In the diabetic
group, no differences in blood glucose levels were ob-
served between the control and a-lipoic acid–treated rats.
No differences in mean arterial pressure (MAP) were ob-
served between any of the treatment groups (Table 1).
UAE and plasma creatinine
UAE increased by threefold with no change in plasma
creatinine in the diabetic + control group compared to
nondiabetic + control (Table 2). Consistent with its pro-
tective properties, a-lipoic acid treatment reduced albu-
min excretion by 1.6-fold in diabetic animals. In con-
trast, a-lipoic acid actually increased albumin excretion
(1.6-fold) and increased plasma creatinine (1.2-fold) in
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Table 2. Effect of a-lipoic acid on renal function and structure
Control a-Lipoic acid
Nondiabetic Diabetic Nondiabetic Diabetic
Urine albumin excrection mg/24 hours 8.8 x/÷1.3 28.1 x/÷4.6d 14.2 x/÷1.2a 17.8 x/÷1.2b
Plasma creatinine lmol/L 59 ± 6 68 ± 6 86 ± 9.0a 69 ± 7c
Glomerulosclerotic index 0.22 ± 0.01 0.55 ± 0.04d 0.61 ± 0.04b 0.36 ± 0.03b,d
Cortical tubulointerstial fibrosis index 0.42 ± 0.2 1.52 ± 0.05d 1.29 ± 0.2b 1.10 ± 0.05a
Medullary tubulointerstitial fibrosis index 0.56 ± 0.2 2.0 ± 0.1d 0.72 ± 0.2 0.49 ± 0.07a
Data are expressed as mean ± SEM except for urine albumin excretion, which is expressed as geometric mean x/÷ tolerance factor.
aP < 0.05; bP < 0.01 vs. control in same metabolic state; cP < 0.05; dP < 0.05 vs. nondiabetic in same treatment group.
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Fig. 1. Periodic acid-Schiff (PAS) and Masson’s trichrome stains. (A) PAS-stained sections of the renal cortex of the nondiabetic (ND) and
diabetic (D) kidneys treated with a-lipoic acid (LA). Glomerulosclerosis (G) with thickening of basement membranes of the proximal tubules (pt),
mesangial expansion (arrow heads), and inflammatory infiltrates (arrows). Masson’s trichrome-stained sections of the renal cortex (B) and medulla
(C) of nondiabetic (ND) and diabetic (D) kidneys treated with a-lipoic acid (LA). Outlined are areas of tubulointerstitial fibrosis, accumulation of
extracellular matrix (ECM) proteins, capillary occlusion, and increased proliferation of interstitial fibroblasts (original magnification ×400).
nondiabetic animals compared to nondiabetic + controls
(Table 2).
Glomerulosclerosis and tubulointerstitial fibrosis
The kidneys of nondiabetic + control rats exhibited
normal cortical (Fig. 1) and medullary (Fig. 1B) morphol-
ogy. Mild glomerulosclerosis, characterized by glomeru-
lar basement membrane thickening and mesangial
expansion was observed in diabetic + control animals,
with a 2.6-fold greater glomerulosclerotic index com-
pared to that of nondiabetic + control (Table 2). Treat-
ment with a-lipoic acid reduced glomerulosclerosis in
the diabetic group by 1.5-fold compared to diabetic +
control; however, treatment of nondiabetic animals with
a-lipoic acid was associated with moderate glomeru-
losclerosis, similar to that observed in the diabetic + con-
trol group (Fig. 1A). Mild tubulointerstitial fibrosis, char-
acterized by accumulation of extracellular matrix (ECM),
tubular dilatation, and atrophy was observed in the dia-
betic + control animals (Fig. 1B). The tubulointerstitial
fibrosis index was 3.6-fold greater in both the renal cor-
tex and medulla compared to that of nondiabetic + con-
trol (Table 2). Treatment with a-lipoic acid reduced tubu-
lointerstitial fibrosis index in the renal cortex (1.3-fold)
and medulla (1.4-fold) in the diabetic group compared to
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Fig. 1. (continued.)
diabetic + control. However, in the nondiabetic group,
treatment with a-lipoic acid increased tubulointerstitial
fibrosis in the renal cortex by threefold and the medulla
by 1.3-fold compared to nondiabetic + control group.
NADPH-stimulated superoxide (O·−2 ) generation
NADPH-stimulated O·−2 generation was increased in
both the renal cortex (5.5-fold) and medulla (threefold)
in the diabetic + control group compared to nondiabetic
+ control (Fig. 2). While treatment with a-lipoic acid
reduced NADPH-stimulated O·−2 generation in the cor-
tex by 3.4-fold and in the medulla by twofold of diabetic
kidneys, a-lipoic acid increased NADPH-stimulated O·−2
generation in the renal cortex (1.8-fold) and medulla (3.6-
fold) of nondiabetic kidneys compared to nondiabetic +
control (Fig. 2).
Renal excretion of 8-iso
Renal excretion of 8-iso increased by 3.5-fold in the di-
abetic + control group compared to nondiabetic + con-
trol (Fig. 3). While treatment with a-lipoic acid did not
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Fig. 2. Nicotinamide adenine dinucleotide phosphate (NADPH)-
stimulated superoxide anion (O·−2 ) generation in the renal cortex and
medulla in nondiabetic (ND) and diabetic (D) kidneys treated with
a-lipoic acid (LA). (A) Cortical NADPH-stimulated O·−2 levels. (B)
Medullary NADPH-stimulated O·−2 levels. Data are expressed as mean± SEM (N = 5 per group). aP < 0.05; aaP < 0.01 vs. control in same
metabolic state; bP < 0.05; bbP < 0.01 vs. nondiabetic in same treatment
group.
affect 8-iso excretion levels in the diabetic group, a-lipoic
acid increased 8-iso excretion in the nondiabetic group by
2.6-fold.
NADPH oxidase subunit immunolocalization
and protein expression
p22phox protein was immunolocalized to the macula
densa and distal tubule (Fig. 4), which is similar in dis-
tribution to that previously observed in the normal rat
kidney [33]. Consistent with our O·−2 results, the inten-
sity of p22phox immunostaining was increased in diabetes
and attenuated with a-lipoic acid treatment. Western blot
analysis confirmed the immunohistochemical observa-
tion, showing that p22phox protein expression was up-
regulated in the cortex (fourfold) and medulla (twofold)
in diabetes, and this increase was attenuated by a-lipoic
acid treatment (Fig. 5).
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Fig. 3. Excretion of 8-isoprostane (8-iso) prostaglandin F2a. in nondi-
abetic (ND) and diabetic (D) kidneys treated with a-lipoic acid (LA).
Data are expressed as mean ± SEM (N = 5 per group). aP < 0.05 vs.
control in same metabolic state; bbP < 0.01 vs. nondiabetic in the same
treatment group.
p47phox protein was immunolocalized to podocytes
and distal tubule (Fig. 4), consistent with previous ob-
servations in the normal kidney [33]. While the overall
intensity of p47phox immunostaining increased in dia-
betes, p47phox also stained to proximal tubules in dia-
betic kidneys, and this was attenuated with a-lipoic acid
treatment (Fig. 4). Consistent with our immunolocaliza-
tion studies, immunoblot analysis showed the p47phox
protein expression was increased in the cortex (1.4-fold)
and medulla (1.7-fold) in diabetes, and this was attenu-
ated with a-lipoic acid treatment (Fig. 5). Expression of
both p22phox and p47phox was increased in nondiabetic
+ a-lipoic acid compared to the nondiabetic + control
kidneys.
DISCUSSION
This study demonstrates that dietary supplementation
with 30 mg/kg a-lipoic acid for 12 weeks prevents the
increase in albuminuria and development of glomeru-
losclerosis and tubulointerstitial fibrosis associated with
diabetic nephropathy. Our studies indicate that one of
the mechanisms by which a-lipoic acid exerts this reno-
protective effect is via decreasing oxidative stress, specif-
ically, by reducing NADPH-induced generation of O·−2
and regulating the expression of NADPH oxidase sub-
units. Most interestingly, our study shows that the dietary
supplementation with the same dose of a-lipoic acid is
associated with a decline in renal function and develop-
ment of glomerulosclerosis and tubulointerstitial fibrosis
in the nondiabetic kidney. Thus, these findings indicate
that, although a-lipoic acid is renoprotective in diabetic
nephropathy, it has detrimental effects to the healthy
kidney.
Our study confirms the previously reported findings
that dietary supplementation with a-lipoic acid atten-
uates albuminuria and renal pathology associated with
diabetic nephropathy in the streptozotocin-induced di-
abetic rat [24, 34, 35]. Studies in other animal models
have reported that the beneficial effects of a-lipoic acid
are mainly exerted through reducing glycemia and blood
pressure [36, 37]. However, our study clearly demon-
strates that a-lipoic acid is renoprotective through reduc-
ing oxidative tissue damage, rather than control of glu-
cose or blood pressure (no differences in glucose levels or
blood pressure were observed between the diabetic ani-
mals on control or a-lipoic acid–supplemented diet). An
antioxidant effect of a-lipoic acid in diabetic nephropa-
thy has also been suggested by others [35], and our study
extends these findings to provide a mechanistic insight to
explain at least part of the antioxidant effects of a-lipoic
acid.
In diabetes, reactive oxygen species are generated from
an excess shunting of glucose into the polyol and glu-
cosamine pathways [38], which leads to the formation
and activation of protein kinase C, formation of AGEs
and glycation [39, 40]. This leads to tissue damage by
increased synthesis of ECM proteins and enhanced ex-
pression of inflammatory mediators, thereby contribut-
ing to glomerulosclerosis and tubulointerstitial fibrosis in
the kidney [41]. Our study shows that diabetes is asso-
ciated with increased oxidative stress in both the renal
cortex and medulla, as measured by NADPH-induced
O·−2 generation. Previous studies have demonstrated that
a-lipoic acid also improves other markers of oxidative
stress in the diabetic kidney, including glutathione and
malondialdehyde [35, 42]. Although our study shows that
a-lipoic acid exerts its renal antioxidant effects through
decreasing NADPH-induced O·−2 generation, no effects
of a-lipoic acid on 8-iso excretion were observed in di-
abetic rats. This is most likely due to extrarenal produc-
tion of O·−2 by other oxidases not affected by a-lipoic
acid. Our data also demonstrate that a-lipoic acid de-
creases the diabetes-associated up-regulation of p22phox
and p47phox expression, the two NADPH oxidase sub-
units. Previous studies have demonstrated that one of the
mechanisms contributing to increased oxidative stress in
the diabetic kidney is increased expression of NADPH
oxidase subunits, namely p47phox, p67phox, and NOX4
[2, 43]. In the spontaneously hypertensive rat, treatment
with antioxidants, including a-tocopherol and ascorbic
acid, reduces the expression of these subunits [44]. To
date, there are no reports on the effects of antioxidants
on the regulation of NADPH oxidase subunits in dia-
betic nephropathy. Our study clearly demonstrates that
a-lipoic acid reduces oxidative stress by regulating the
expression of enzymes involved in formation of reactive
oxygen species.
An unexpected and startling finding in our study was
that dietary supplementation with a-lipoic acid, at doses
that prevent the decline in renal function and pathology in
Bhatti et al: a-Lipoic acid in diabetic nephropathy 1377
p22phox p47phox
ND
D
ND+LA
D+LA Fig. 4. Immunohistochemical localization of
nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase subunits in nondiabetic
(ND) and diabetic (D) kidneys treated with
a-lipoic acid (LA). Abbreviations are: Md,
macula densa; pt, proximal tubule; dt, distal
tubule; arrows, podocytes (original magnifica-
tion ×400).
diabetic nephropathy, are detrimental to the healthy kid-
ney. In nondiabetic rats, treatment with a-lipoic acid is as-
sociated with a decline in creatinine clearance, increases
in albuminuria, glomerulosclerosis, tubulointerstitial fi-
brosis, and increases in NADPH-induced O·−2 generation
and 8-iso excretion. These changes are similar to those
observed in the kidneys of untreated diabetic rats. It is
quite surprising that none of the previous studies exam-
ining the effects of a-lipoic acid in diabetic nephropathy
have ever reported the effects of a-lipoic acid in the non-
diabetic kidney, and, according to our findings, in con-
trast to the diabetic animals where a-lipoic acid exerts
a protective effect, a-lipoic acid appears to have a dele-
terious effect in nondiabetic animals. Scott et al [45] re-
ported that DHLA, the reduced metabolite of a-lipoic
acid, may have pro-oxidant effects, via its ability to re-
duce iron and generate reactive sulfur-containing radicals
that can damage proteins such as alpha 1-antiproteinase
and creatine kinase [45]. a-lipoic acid and DHLA have
also been shown to stimulate O·−2 production in rat liver
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Fig. 5. Renal expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit protein in nondiabetic (ND) and diabetic (D)
kidneys treated with a-lipoic acid (LA). Top panels in each graph are representative Western blots. Bottom panels in each graph are densitometric
analyses of the blots shown above. Data are expressed as mean ± SEM (N = 6 per group). aP < 0.05; aaP < 0.01 vs. control in same metabolic state;
bP < 0.05; bbP < 0.01 vs. nondiabetic in the same treatment group.
mitochondria and submitochondrial particles and in cul-
tured 3T3-L1 adipocytes in response to high glucose stim-
uli [46]. Consistent with these findings, we observed that
a-lipoic acid increases NADPH-induced O·−2 and expres-
sion of p47phox in the nondiabetic kidney and thus by
acting as a pro-oxidant, causes deleterious effects in the
healthy kidney.
The detrimental effects of a-lipoic acid on renal func-
tion and pathology may be dose-related. We have cho-
sen a dose of a-lipoic acid previously reported to have
beneficial effects in the diabetic kidney [34]. Although
our studies confirm these findings, we also show that this
same dose of a-lipoic acid (30 mg/kg body weight) com-
promises renal structure and function under nondiabetic
conditions. A wide range of daily recommended doses of
a-lipoic acid have been reported and used in human tri-
als, ranging from 100 to 1800 mg/day [47–49]; although
little attention has been paid to this dose relative to body
weight, duration of the trial or underlying physiologic
state, especially relating to renal function. In a trial us-
ing dietary supplementation with a-lipoic acid at a dose
of 600 mg/day for 3 months, a reduction of UAE was
observed in type 2 diabetic patients [48]; however, no ef-
fects of a-lipoic acid in healthy individuals were reported
in this study. Another human trial reported that a-lipoic
acid at a dose of 600mg/day for 8 weeks in healthy volun-
teers (age group ∼38 years of age) reduced 8-iso excre-
tion [50]; however, no other markers of oxidative stress
or renal function were reported. In experimental animal
models, a-lipoic acid has been used in the range of 25
to 100 mg/kg/day [24, 34, 35]. It is quite intriguing, how-
ever, that none of these animal studies report the findings
in the control, healthy animals. Thus, our results stress
the importance of monitoring the dose of a-lipoic acid
supplementation, duration of treatment and its potential
harmful effects in the healthy kidney.
Based on the findings of our study, we conclude that
a-lipoic acid may exert both pro- and antioxidant effects,
depending on the underlying physiologic and metabolic
state. While a-lipoic acid is renoprotective in diabetic
nephropathy, it may have potential harmful effects in an
otherwise healthy kidney.
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